Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Nagatani Y, Funakoshi Y, Suto H, Imamura Y, Toyoda M, Kiyota N, Yamashita K, Minami H. Nagatani Y, et al. J Cancer Res Ther. 2021 Jul-Sep;17(4):1093-1100. doi: 10.4103/jcrt.JCRT_1222_20. J Cancer Res Ther. 2021. PMID: 34528569 Free article.
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H, Kiyota N, Otsuki N, Imamura Y, Chayahara N, Suto H, Nagatani Y, Toyoda M, Mukohara T, Nibu KI, Kasahara T, Ito Y, Miya A, Hirokawa M, Miyauchi A, Minami H. Goto H, et al. Among authors: nagatani y. Auris Nasus Larynx. 2018 Dec;45(6):1249-1252. doi: 10.1016/j.anl.2018.05.003. Epub 2018 May 18. Auris Nasus Larynx. 2018. PMID: 29779695
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.
Imamura Y, Tanaka K, Kiyota N, Hayashi H, Ota I, Arai A, Iwae S, Minami S, Yane K, Yamazaki T, Nagatani Y, Toyoda M, Takahama T, Sakai K, Nishio K, Otsuki N, Nibu KI, Minami H. Imamura Y, et al. Among authors: nagatani y. Med Oncol. 2021 Sep 22;38(11):128. doi: 10.1007/s12032-021-01581-z. Med Oncol. 2021. PMID: 34550483 Clinical Trial.
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H. Funakoshi Y, et al. Among authors: nagatani y. J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. J Infect Chemother. 2022. PMID: 35090826 Free PMC article.
Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.
Funakoshi Y, Yakushijin K, Ohji G, Matsutani T, Hojo W, Sakai H, Matsumoto S, Watanabe M, Kitao A, Saito Y, Kawamoto S, Yamamoto K, Koyama T, Nagatani Y, Kimbara S, Imamura Y, Kiyota N, Ito M, Minami H. Funakoshi Y, et al. Among authors: nagatani y. Br J Haematol. 2023 Aug;202(3):504-516. doi: 10.1111/bjh.18932. Epub 2023 Jun 22. Br J Haematol. 2023. PMID: 37349876
175 results